{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096188","form_type":"8-K","ticker":"TKNO","cik":"0001850902","company_name":"Alpha Teknova, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.913892+00:00","generated_at":"2026-05-31T09:49:59.425410+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alpha Teknova Q2 revenue $9.6M, down 17% YoY; reaffirms FY2024 guidance $35-38M","bullets":["Revenue $9.6M, down 17% YoY but up 3% sequentially; Lab Essentials flat, Clinical Solutions down 57%.","Net loss $5.4M ($0.13/share) vs $7.2M prior year; Adjusted EBITDA negative $2.6M.","Gross margin fell to 29.2% from 43.9% due to lower Clinical Solutions revenue and higher overhead.","Raised $15.4M equity in July 2024; cash $18.6M, debt $12.1M; confirms free cash outflow <$18M for FY.","Clinical customers up 26% to 43; launched Express-Tek and RUO+ offerings."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096188","json":"https://secwatch.observer/filing/0000950170-24-096188.json","markdown":"https://secwatch.observer/filing/0000950170-24-096188.md","text":"https://secwatch.observer/filing/0000950170-24-096188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850902/000095017024096188/0000950170-24-096188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850902/000095017024096188/tkno-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:49:59.425410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}